RxDoctor Payments Data

Alexander Kudryk, MD

Internal Medicine · Bridgewater, NJNPI 1912938671

Payments from drug & device makers

$4,099in general payments, 2019–2025

Across 297 payments — averaging $13.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$566
  • AstraZeneca$383
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$348
  • AbbVie$259
  • Johnson & Johnson$246
  • Amarin Pharma, Inc.$222
  • plus $2K from 33 others
$150in research payments, 2019–2025

Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$150

What the payments were for

  • Consulting fees$1002%
  • Speaking & faculty fees$130%
  • Food & beverage$3,86394%
  • Education$1223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,099 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$9,968
Medicare patients
25
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$9,337
JanuviaSitagliptin Phosphate13$7,397
MyrbetriqMirabegron13$5,940
Aspirin-Dipyridamole ErAspirin/Dipyridamole13$2,655
Ursodiol13$1,510
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc15$1,506
Tamsulosin Hcl45$1,394
Amlodipine Besylate99$1,342
Lisinopril52$1,058
Gabapentin80$1,057
Atorvastatin Calcium66$943
Mirtazapine36$899
Bumetanide56$851
Pantoprazole Sodium34$769
Potassium Chloride42$750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$213$9,33726 claims
MerckJanuvia$111$7,39713 claims
Astellas Pharma US IncMyrbetriq$122$5,94013 claims
Almatica Pharma LLCSertraline Hcl$28$57732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Bridgewater

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →